تعداد نشریات | 20 |
تعداد شمارهها | 1,149 |
تعداد مقالات | 10,518 |
تعداد مشاهده مقاله | 45,416,242 |
تعداد دریافت فایل اصل مقاله | 11,292,105 |
Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease | ||
Iranian Journal of Colorectal Research | ||
دوره 6، شماره 1، خرداد 2018 اصل مقاله (284.99 K) | ||
نوع مقاله: Research/Original Article | ||
نویسندگان | ||
Tsvetelina Veselinova Velikova* 1؛ Zoya Angelova Spassova2؛ Lyuben Mitkov Milatchkov2؛ Dobriana Georgieva Panova2؛ Ekaterina Ivanova Ivanova - Todorova3؛ Kalina Dinkova Tumangelova - Yuzeir3؛ Ekaterina Krasimirova Kurteva3؛ Dobroslav Stanimirov Kyurkchiev3؛ Siragan Arshavir Deredjan2؛ Rosen Kirilov Nikolov2؛ Iskra Petrova Altankova1؛ Lyudmila Mateva Vladimirova2 | ||
1Clinical Immunology, University Hospital Lozenetz, Sofia, Bulgaria | ||
2Clinic of Gastroenterology, University Hospital St. Ivan Rilski, Sofia, Bulgaria | ||
3Department of Clinical Laboratory and Clinical Immunology, University Hospital St. Ivan Rilski, Sofia, Bulgaria | ||
چکیده | ||
Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti - tumor necrosis factor (TNF) should be evaluated in addition to biomarkers to determine the response to therapy. Objectives: The current study aimed at following up fecal calprotectin (FC), perinuclear anti - neutrophil cytoplasmic antibodies (pANCA), anti - Saccharomyces cerevisiae antibodies (ASCA), and anti - nuclear antibodies (ANA) in patients with CD on anti-TNF therapy. Methods: A total of 57 patients with CD and the mean age of 4015 years (ranged: 20 - 75) were monitored after initiation of anti - TNFa treatment. Stool samples were tested for FC (Alegria automated the enzyme - linked immunosorbent assay (ELISA) system), and serum samples for ANCA, ANA (indirect immunofluorescence - IIF), and ASCA (ELISA) in the beginning and after six months on immunosuppressive therapy plus anti - TNFa agents. Results: Itwasobserved that all patients withCDhadsignificantly decreased FC levels after anti -TNFatherapy (963.97mg/kginitially vs. 268.42 mg/kg after treatment; P = 0.043). Moreover, in 75% of patients, FC levels dropped below the cutoff value of 50 mg/kg. Positive for ASCAIgA/IgG were 17/24 tested patients, butnodifferences were observed regarding the application of anti - TNFa therapy. However, the titers of pANCA decreased in four patients after anti - TNFa treatment. Conclusions: Initial and follow - up measurements of some immunological markers such as FC and pANCA could be of benefit for patients with CD in anti - TNF therapy, whereas others such as ANA and ASCA were not useful to monitor the therapy. | ||
کلیدواژهها | ||
TNFa Inhibitors؛ Immunological Biomarkers؛ Therapy Monitoring | ||
آمار تعداد مشاهده مقاله: 181 تعداد دریافت فایل اصل مقاله: 139 |